TAIHO PHARMA

Contact Us
Japanese
  • About Taiho
  • Our Business
  • Our Science
  • Product Lineup
  • News Releases

CLOSE

About Taiho

  • About Taiho TOP
  • Corporate Philosophy
  • President's Message
  • Corporate Data
  • Financial Highlights
  • Globalization
  • Major Subsidiaries
  • Corporate Social Responsibility
  • History
  • Otsuka Holdings Co., Ltd.

Our Business

  • Our Business TOP
  • Research & Development
  • Production
  • Marketing

Our Science

  • Our Science TOP
  • Product Pipeline
  • Discovery and Preclinical Research
  • Clinical Development
  • Policy
  • Otsuka group of companies 100th Anniversary

    100th

  • Exploring hidden
    possibilities for
    people awaiting
    new medicines

    sample

PREV
NEXT
  • ■We mourn the loss of those who have died from COVID-19, extend our sympathies to their loved ones, wish COVID-19 survivors rapid and permanent recoveries, and express our gratitude to medical professionals and others who support the ill.

  • ■Otsuka Holdings Donations for Humanitarian Support to Ukrainian People

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

  • RSS
  • More
  • June 20, 2022

    Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)

  • June 01, 2022

    Taiho Pharmaceutical to Donate a Total of 4.17 Million Yen to Three Projects Addressing Issues in the Field of Oncology "The First Taiho Smile Support"

  • May 25, 2022

    Taiho Pharmaceutical Announces the Launch of Selective NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

  • May 12, 2022

    Taiho Pharmaceutical and Cullinan Oncology Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho's Acquisition of Cullinan Pearl (PDF:139.2 KB)

  • April 21, 2022

    Otsuka Group Joins RE100 International Initiative - Committed to 100% Renewable Energy -

Information

  • May 13, 2022

    Otsuka Holdings announces FY2022 Q1 financial results

  • July 12, 2018

    Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan(PDF:165.9 KB)

  • Terms of Use
  • Privacy Statement
  • Sitemap
  • Otsuka Otsuka Group
  • Otsuka Holdings
  • Otsuka Pharmaceutical
  • Otsuka Pharmaceutical Factory
  • Otsuka Warehouse
  • Otsuka Chemical
  • Otsuka foods
  • Otsuka Medical Devices

Copyright © TAIHO PHARMACEUTICAL CO., LTD. 2022 All rights reserved.